MedAnnex Ltd

Home page - Medannex | Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. "Annexin-A1 may prove a very significant clinical target, and blocking its activity with MDX-124 could represent a completely new and exciting way to treat cancer. We are delighted to be leading the first-in-human study." Professor Daniel Palmer,Liverpool Clinical